
(BAS)
BNB Attestation Service (BAS) price prediction for 2026-2030Not listed
How has BNB Attestation Service (BAS) performed this year? What are the short-term outlooks (1 week, 1 month, 3 months) and the long-term forecast for 2026-2030? We analyze and forecast BAS's future price based on recent trends, historical data, and technical indicators such as Moving Averages (MA), RSI, and MACD. You can also use our price prediction tool to estimate potential returns by setting your target growth rate.
BNB Attestation Service (BAS) price
Last updated: Aug 19, 2026, 19:19:59
24h high
0.027710 USD
Market cap
66.64M USD
24h low
0.025400 USD
24h volume
1.44M USD
BNB Attestation Service (BAS) price
0.02665 USD
Date
--
Enter your expected growth for BNB Attestation Service to calculate its future value
Current price
0.02665 USD
Momentum
Bullish
14D RSI
60.96
50D SMA
0.027831 USD
200W SMA
0.018851 USD
Fear & Greed
51
1. Weekly EMA 200
The weekly EMA 200 is a widely used bull/bear market divider and long-term trend line in crypto.
2. Daily EMA 50
3. MACD trend & reversal signals
Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.
Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.